Literature DB >> 14578161

Effect of chemopreventive agents on separate stages of progression of benzo[alpha]pyrene induced lung tumors in A/J mice.

R D Estensen1, M M Jordan, T S Wiedmann, A R Galbraith, V E Steele, L W Wattenberg.   

Abstract

The effects of aerosol budesonide and dietary myo-inositol on progression of benzo[alpha]pyrene (B[alpha]P) induced carcinogenesis were studied in A/J mouse lung. First, we determined when to intervene in the carcinogenesis process by exposing several animals to B[alpha]P at 100 and 150 mg/kg of body wt. Groups of these animals were necropsied from 1 to 36 weeks post-carcinogen. The presence of different categories of lung tumors was noted over the 36 week time period. Hyperplasia first appeared approximately 6 weeks post-carcinogen followed by adenoma at 9 weeks, then by carcinoma at 26 weeks. From this temporal sequence we determined we could test for effects of preventive agents on progression to hyperplasia by intervening at 3 weeks, for effects on progression to adenoma by intervening at 6 weeks and for effects on progression to carcinoma by intervention at 12 weeks. Intervention at 3 weeks post-carcinogen with aerosolized budesonide delayed both hyperplasia and adenoma formation. Once hyperplasia appeared in budesonide treated animals, however, it increased at the same rate as in control animals, indicating a delay in progression. Progression from adenoma to carcinoma was reduced when budesonide was given 12 weeks post-carcinogen. Dietary myo-inositol failed to suppress progression from adenoma to carcinoma when started 12 weeks post-carcinogen. In summary, budesonide is a chemopreventive agent that has inhibitory effects on B[alpha]P induced carcinogenesis of the lung in A/J mice at all stages of progression from hyperplasia formation to cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14578161     DOI: 10.1093/carcin/bgg196

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  27 in total

Review 1.  Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence.

Authors:  Silvio De Flora; Gancho Ganchev; Marietta Iltcheva; Sebastiano La Maestra; Rosanna T Micale; Vernon E Steele; Roumen Balansky
Journal:  Trends Pharmacol Sci       Date:  2015-12-23       Impact factor: 14.819

2.  Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol.

Authors:  Nese Unver; Oliver Delgado; Kirubel Zeleke; Amber Cumpian; Ximing Tang; Mauricio S Caetano; Hong Wang; Hiroyuki Katayama; Hua Yu; Eva Szabo; Ignacio I Wistuba; Seyed Javad Moghaddam; Samir M Hanash; Edwin J Ostrin
Journal:  Int J Cancer       Date:  2017-12-23       Impact factor: 7.396

3.  Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer.

Authors:  Alfred Haynes; Madhu Sudhan Shaik; Abhijit Chatterjee; M Singh
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

4.  Modulation of microRNA expression by budesonide, phenethyl isothiocyanate and cigarette smoke in mouse liver and lung.

Authors:  Alberto Izzotti; Patrizia Larghero; Cristina Cartiglia; Mariagrazia Longobardi; Ulrich Pfeffer; Vernon E Steele; Silvio De Flora
Journal:  Carcinogenesis       Date:  2010-02-09       Impact factor: 4.944

5.  Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease.

Authors:  Tanyalak Parimon; Jason W Chien; Chris L Bryson; Mary B McDonell; Edmunds M Udris; David H Au
Journal:  Am J Respir Crit Care Med       Date:  2006-12-21       Impact factor: 21.405

6.  REV1 is implicated in the development of carcinogen-induced lung cancer.

Authors:  Chad A Dumstorf; Suparna Mukhopadhyay; Elangovan Krishnan; Bodduluri Haribabu; W Glenn McGregor
Journal:  Mol Cancer Res       Date:  2009-01-27       Impact factor: 5.852

Review 7.  New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly.

Authors:  Shyam S Bansal; Abhijeet Joshi; Arvind K Bansal
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 8.  The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.

Authors:  Robert H Shoemaker; Chen S Suen; Cathy A Holmes; Judith R Fay; Vernon E Steele
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

9.  Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J mice.

Authors:  Fekadu Kassie; Stephen Kalscheuer; Ilze Matise; Linan Ma; Tamene Melkamu; Pramod Upadhyaya; Stephen S Hecht
Journal:  Carcinogenesis       Date:  2009-07-22       Impact factor: 4.944

10.  Combinations of N-Acetyl-S-(N-2-Phenethylthiocarbamoyl)-L-Cysteine and myo-inositol inhibit tobacco carcinogen-induced lung adenocarcinoma in mice.

Authors:  Fekadu Kassie; Ilze Matise; Mesfin Negia; David Lahti; Yunqian Pan; Robyn Scherber; Pramod Upadhyaya; Stephen S Hecht
Journal:  Cancer Prev Res (Phila)       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.